Targeted Therapy for Muscle-Invasive Bladder Cancer

Targeted therapy uses drugs to target specific changes in cancer cells that help them grow, divide, and spread. Targeted therapy drugs are designed to be more precise. They fight cancer cells while causing less harm to other cells in the body.  

These are the latest targeted therapies that are approved to treat muscle-invasive bladder cancer. New treatments become available all the time, so this may not be a complete list.

Please note: The side effects listed here do not represent a comprehensive list. It's important to discuss all potential side effects of a drug with your health care team. Be sure to tell your health care team about any side effects you do have.

All Available Treatments

Intravenous =
Pill =

Treatment Type

TKI

Drug Name
Balversa™ (erdaitinib) (Pill)
Important Things to Know

This medication can be used for patients with FGFR3 mutations.

Treatment Type

Trop-2 Directed Antibody and Topoisomerase Inhibitor Conjugate

Drug Name
Trodelvy® (sacituzumab govitecan) (IV)
Important Things to Know
  • This medication can be used for patients with PD-L1 biomarker.
  • Low blood counts are a potential side effect that may put you at risk for anemia, infection, or bleeding.

Treatment Type

Monoclonal antibody

Drug Name
Padcev® (enfortumab-vedotin) (IV)
Important Things to Know
  • This medication can be used for patients with PD-L1 biomarker.
  • Low blood counts are a potential side effect that may put you at risk for anemia, infection, or bleeding.